Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
FOLD Stock | USD 9.90 0.54 5.77% |
About 55% of Amicus Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Amicus Therapeutics suggests that some traders are interested. The current market sentiment, together with Amicus Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Amicus Therapeutics stock news signals to limit their universe of possible portfolio assets.
Amicus |
PRINCETON, N.J., Nov. 01, 2024 -- Amicus Therapeutics today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 230 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 800 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors
Read at finance.yahoo.com
Amicus Therapeutics Current Investor Sentiment
Panic Vs Confidence
55
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Amicus Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Amicus Therapeutics.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentDisposing |
Amicus Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Amicus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Amicus Therapeutics Historical Investor Sentiment
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Amicus Therapeutics.
Amicus Therapeutics Fundamental Analysis
We analyze Amicus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Amicus Therapeutics is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Amicus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amicus Therapeutics stock to make a market-neutral strategy. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics with similar companies.
Peers
Amicus Therapeutics Related Equities
EWTX | Edgewise Therapeutics | 18.36 | ||||
AGIO | Agios Pharm | 9.55 | ||||
ARGX | Argenx NV | 4.19 | ||||
KURA | Kura Oncology | 3.63 | ||||
BPMC | Blueprint Medicines | 2.36 | ||||
CRNX | Crinetics Pharmaceuticals | 1.81 | ||||
HRMY | Harmony Biosciences | 1.66 | ||||
DYN | Dyne Therapeutics | 1.44 | ||||
DNLI | Denali Therapeutics | 1.39 | ||||
CYTK | Cytokinetics | 0.76 | ||||
RVMD | Revolution Medicines | 0.18 | ||||
INBX | Inhibrx | 0.41 | ||||
DAWN | Day One | 0.47 | ||||
BMRN | Biomarin Pharmaceutical | 0.71 | ||||
RARE | Ultragenyx | 0.83 | ||||
MLYS | Mineralys Therapeutics, | 2.22 | ||||
ARVN | Arvinas | 2.62 | ||||
INCY | Incyte | 3.22 | ||||
LEGN | Legend Biotech | 6.01 | ||||
MREO | Mereo BioPharma | 7.75 |
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data |